NCT04568174 - First in Human Study to Test the Safety and Preliminary Efficacy of PPSGG in Patients With Anti-MAG Neuropathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 17, 2020

Primary Completion Date

September 23, 2021

Study Completion Date

September 23, 2021

Conditions

Anti-MAG Neuropathy

Interventions

DRUG

PPSGG

an antibody scavenger of pathogenic anti-MAG immunoglobulin M (IgM) autoantibodies

DRUG

Placebo

A standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection

Trial Locations (7)

13385

Referral centre for neuromuscular diseases and ALS, hôpital La Timone, Marseille

94275

Département de Neurologie Pôle Neurosciences Centre de Référence des Neuropathies Amyloïdes Familiales et autres Neuropathies Périphériques Rares Centre Hospitalier Universitaire de Bicêtre, Paris

87 042

Service de Neurologie Centre de Référence Neuropathies Périphériques Rares, CHU Limoges, Limoges

Unknown

UMC Utrecht Cancer Center, Utrecht

Barcelona, Barcelona

Lausanne, Lausanne

WC1N 3bg

National hospital for neurology and neurosurgery, Queen London, London